Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

608

Citations

10

References

2001

Year

Elise A. Olsen, Madeleine Duvic, Arthur E. Frankel, Ann Martin, Eric C. Vonderheid, Brian V. Jegasothy, Gary S. Wood, Michael D. Gordon, Peter Heald, Allan R. Oseroff,

Journal of Clinical Oncology

Abstract

Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.

References

	Year	Citations

Page 1